SUPPLEMENTARY MATERIALS Supplementary
: RXDX-105 inhibits target kinases and intracellular signaling pathways. Neuroblastoma cell lines were treated with either vehicle or decreasing doses of RXDX-105 for 24 hours in combination with 5 μM 13-cis-retinoic acid. Cells were lysed and Western blots were performed to assess MEK expression and phosphorylation. GAPDH expression is shown as a loading control.
Supplementary Figure 2: Sensitivity to RXDX-105 is related to RAS-MAPK gene expression. Neuroblastoma cell line gene
expression from [25] was assessed to evaluate for differences in gene pathway expression using pathways from the Molecular Signatures Database [36] underlying relative cell line sensitivities to RXDX-105. Cell lines with IC50 values less than 8 µM were considered more sensitive, while cell lines with IC50 values above 8 µM were considered less sensitive. Increased pathway gene expression is shown in red, while decreased pathway gene expression is shown in blue.
